News articles about Audentes Therapeutics (NASDAQ:BOLD) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Audentes Therapeutics earned a news impact score of 0.14 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.8486728101968 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of Audentes Therapeutics opened at $38.12 on Friday, according to MarketBeat Ratings. Audentes Therapeutics has a fifty-two week low of $13.90 and a fifty-two week high of $42.61. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -11.21 and a beta of 1.22.
Audentes Therapeutics (NASDAQ:BOLD) last released its earnings results on Wednesday, May 9th. The biotechnology company reported ($0.74) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.07. sell-side analysts forecast that Audentes Therapeutics will post -3.31 EPS for the current year.
Several equities research analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $37.00 price target on shares of Audentes Therapeutics in a report on Wednesday, February 7th. Raymond James reissued a “hold” rating on shares of Audentes Therapeutics in a report on Friday, May 11th. Mizuho reissued a “hold” rating and issued a $38.00 price target on shares of Audentes Therapeutics in a report on Monday, May 21st. William Blair reissued a “buy” rating on shares of Audentes Therapeutics in a report on Thursday, May 17th. Finally, Wedbush raised their price target on Audentes Therapeutics from $49.00 to $56.00 and gave the stock an “outperform” rating in a report on Thursday, May 10th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $37.22.
In related news, CEO Matthew R. Patterson sold 20,300 shares of Audentes Therapeutics stock in a transaction dated Monday, May 21st. The stock was sold at an average price of $38.15, for a total transaction of $774,445.00. Following the completion of the sale, the chief executive officer now owns 13,600 shares of the company’s stock, valued at $518,840. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Mary Newman sold 10,000 shares of Audentes Therapeutics stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $30.36, for a total value of $303,600.00. Following the sale, the senior vice president now directly owns 4,076 shares of the company’s stock, valued at approximately $123,747.36. The disclosure for this sale can be found here. Insiders have sold 1,158,407 shares of company stock valued at $40,276,467 in the last ninety days. Corporate insiders own 6.60% of the company’s stock.
About Audentes Therapeutics
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.